BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32088875)

  • 1. In Vivo Administration of Splice Switching PNAs Using the mdx Mouse as a Model System.
    Brolin C; Lim EWK; Nielsen PE
    Methods Mol Biol; 2020; 2105():241-250. PubMed ID: 32088875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice.
    Yin H; Lu Q; Wood M
    Mol Ther; 2008 Jan; 16(1):38-45. PubMed ID: 17968354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse.
    Yin H; Betts C; Saleh AF; Ivanova GD; Lee H; Seow Y; Kim D; Gait MJ; Wood MJ
    Mol Ther; 2010 Apr; 18(4):819-27. PubMed ID: 20068555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approaches for Systemic Delivery of Dystrophin Antisense Peptide Nucleic Acid in the mdx Mouse Model.
    Brolin C; Lim EWK; Grizot S; Olsen CH; Yavari N; Krag TO; Nielsen PE
    Nucleic Acid Ther; 2021 Jun; 31(3):208-219. PubMed ID: 32678992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
    Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ
    J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
    Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
    J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results.
    van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A
    Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
    Maruyama R; Yokota T
    Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
    Yin H; Moulton HM; Betts C; Seow Y; Boutilier J; Iverson PL; Wood MJ
    Hum Mol Genet; 2009 Nov; 18(22):4405-14. PubMed ID: 19692354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers.
    Williams JH; Sirsi SR; Latta DR; Lutz GJ
    Mol Ther; 2006 Jul; 14(1):88-96. PubMed ID: 16488666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.
    Cao L; Han G; Gu B; Yin H
    PLoS One; 2014; 9(11):e111079. PubMed ID: 25365558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.
    Relizani K; Goyenvalle A
    Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy.
    Jirka SMG; 't Hoen PAC; Diaz Parillas V; Tanganyika-de Winter CL; Verheul RC; Aguilera B; de Visser PC; Aartsma-Rus AM
    Mol Ther; 2018 Jan; 26(1):132-147. PubMed ID: 29103911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exon 51 Skipping Quantification by Digital Droplet PCR in del52hDMD/mdx Mice.
    Hiller M; Spitali P; Datson N; Aartsma-Rus A
    Methods Mol Biol; 2018; 1828():249-262. PubMed ID: 30171546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide conjugation of 2'-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice.
    Jirka SM; Heemskerk H; Tanganyika-de Winter CL; Muilwijk D; Pang KH; de Visser PC; Janson A; Karnaoukh TG; Vermue R; 't Hoen PA; van Deutekom JC; Aguilera B; Aartsma-Rus A
    Nucleic Acid Ther; 2014 Feb; 24(1):25-36. PubMed ID: 24320790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Intravenous Administration of Antisense Therapeutics for Combinatorial Dystrophin and Myostatin Exon Splice Modulation.
    Lu-Nguyen N; Dickson G; Malerba A
    Methods Mol Biol; 2018; 1828():343-354. PubMed ID: 30171552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
    Echigoya Y; Yokota T
    Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vivo Evaluation of Single-Exon and Multiexon Skipping in mdx52 Mice.
    Mizobe Y; Miyatake S; Takizawa H; Hara Y; Yokota T; Nakamura A; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1828():275-292. PubMed ID: 30171548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.